Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Jul-Aug;25(4):159-64.
doi: 10.5830/CVJA-2014-025.

Epidemiological African day for evaluation of patients at risk of venous thrombosis in acute hospital care settings

Affiliations
Observational Study

Epidemiological African day for evaluation of patients at risk of venous thrombosis in acute hospital care settings

Samuel Kingue et al. Cardiovasc J Afr. 2014 Jul-Aug.

Abstract

Introduction: This study aimed to identify patients at risk for venous thromboembolism (VTE) among all patients hospitalised, and to determine the proportion of at-risk hospital patients who received effective types of VTE prophylaxis in sub-Saharan Africa (SSA).

Methods: A multinational, observational, cross-sectional survey was carried out on 1 583 at-risk patients throughout five SSA countries.

Results: The prevalence of VTE risk was 50.4% overall, 62.3% in medical and 43.8% in surgical patients. The proportion of at-risk patients receiving prophylaxis was 51.5% overall, 36.2% in medical and 64% in surgical patients. Low-molecular weight heparin was the most frequently used prophylactic method in 40.2% overall, 23.1% in medical and 49.9% in surgical patients.

Discussion: This study showed a high prevalence of VTE risk among hospitalised patients and that less than half of all at-risk patients received an American College of Clinical Pharmacy-recommended method of prophylaxis.

Conclusion: Recommended VTE prophylaxis is underused in SSA.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Percentage at-risk patients versus patients that received ACCP-recommended VTE prophylaxis by country.

Similar articles

Cited by

References

    1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B. et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933–938. - PubMed
    1. Heit JA, O’Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ 3rd.. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245–1248. - PubMed
    1. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin study group. N Engl J Med. 1999;341:793–800. - PubMed
    1. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879. - PubMed
    1. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG. et al. Fondaparinux for the prevention of VTE in acutely ill medical patients. Blood. 2003;102 abstract 42.

Publication types